Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
LeMaitre Vascular Inc Market Cap
The LeMaitre Vascular Inc (LMAT) share price is expected to increase by 5.2% over the next year. This is based on calculating the average 12-month share price estimate provided by 8 stock analysts who have covered LMAT. Price targets range from $85 at the low end to $105 at the high end. The current analyst consensus for LMAT is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 8 Wall Street analysts have assigned LMAT 2 buy ratings, 6 hold ratings, and 0 sell ratings. This means that analysts expect LeMaitre Vascular Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on LMAT. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of LMAT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Michael Petusky Barrington Research | Outperform | $92 | Maintains | Sep 20, 2024 |
| Daniel Stauder JMP Securities | Market Outperform | $100 | Maintains | Aug 20, 2024 |
| Michael Petusky Barrington Research | Outperform | $92 | Maintains | Aug 2, 2024 |
| Jason Wittes Roth MKM | Buy | $100 | Reinstates | May 31, 2024 |
| Daniel Stauder JMP Securities | Market Outperform | $77 | Maintains | May 3, 2024 |
| Michael Petusky Barrington Research | Outperform | $79 | Maintains | May 3, 2024 |
| Rick Wise Stifel | Buy | $75 | Upgrade | Apr 26, 2024 |
| Michael Petusky Barrington Research | Outperform | $69 | Maintains | Feb 28, 2024 |
| Brett Fishbin Keybanc | Sector Weight | Initiates | Feb 6, 2024 | |
| Daniel Stauder JMP Securities | Market Outperform | $60 | Initiates | Oct 23, 2023 |
| Suraj Kalia Oppenheimer | Outperform | $70 | Initiates | Sep 6, 2023 |
| Anthony Petrone Jefferies | Hold | $67 | Downgrade | Aug 3, 2023 |
| Michael Petusky Barrington Research | Outperform | $66 | Maintains | Aug 2, 2023 |
| Brooks O'Neil Lake Street | Buy | $75 | Maintains | Aug 2, 2023 |
| Michael Petusky Barrington Research | Outperform | $62 | Upgrade | May 3, 2023 |
| Michael Petusky Barrington Research | Market Perform | Downgrade | Oct 28, 2022 | |
| Anthony Petrone Jefferies | Buy | $70 | Initiates | Sep 16, 2021 |
| Scott Henry Roth Capital | Neutral | $58 | Maintains | Aug 3, 2021 |
Roth Capital | Neutral | $55 | Maintains | May 4, 2021 |
KeyBanc | Sector Weight | Initiates | Feb 12, 2021 |
When did it IPO
2006
Staff Count
614
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. George W. LeMaitre
Market Cap
$2.06B
In 2023, LMAT generated $193.5M in revenue, which was a increase of 19.69% from the previous year. This can be seen as a signal that LMAT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 23 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - LeMaitre (LMAT) has been upgraded to Zacks Rank #1 (Strong Buy), indicating positive earnings outlook and potential for stock price increase.
Why It Matters - LeMaitre's upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and driving the stock price upward in the near term.
Tue, 27 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - LeMaitre Vascular, Inc. (Nasdaq: LMAT) will participate in three investor conferences in September 2024, as announced on August 27, 2024.
Why It Matters - LeMaitre Vascular's participation in investor conferences suggests potential growth opportunities, increased visibility, and engagement with investors, which may impact stock performance.
Tue, 06 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - LeMaitre (LMAT) has been upgraded to a Zacks Rank #1 (Strong Buy) due to increasing optimism about its earnings prospects, indicating potential for stock price growth.
Why It Matters - LeMaitre's upgrade to a Zacks Rank #1 signals strong earnings potential, suggesting increased investor confidence and potential price appreciation for LMAT shares.
Tue, 06 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - HWKN, PPC, and LMAT have been designated as Zacks Rank #1 (Strong Buy) momentum stocks as of August 6, 2024.
Why It Matters - HWKN, PPC, and LMAT's inclusion in the Zacks Rank #1 list signals strong buy momentum, indicating potential for price appreciation and favorable investment opportunities.
Thu, 01 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - LeMaitre Vascular, Inc. (NASDAQ: LMAT) held its Q2 2024 results conference call on August 1, 2024, featuring key executives and analysts from various financial firms.
Why It Matters - LeMaitre Vascular's Q2 2024 results can indicate financial health and growth potential, influencing stock performance and investor confidence in the company's future.
Thu, 01 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - LeMaitre (Nasdaq: LMAT) reported Q2 2024 results, announced a quarterly dividend of $0.16 per share, and issued guidance on future performance.
Why It Matters - LeMaitre's Q2 results and $0.16 dividend signal financial stability and potential growth, influencing stock attractiveness and investor confidence in the company.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
